Company Profile for Fluidigm Corporation

Fluidigm develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio industries. Our proprietary microfluidic systems consist of instruments, and consumables, including chips and reagents. Our proprietary technology enables genetic analyses that in many instances were not previously practical and significantly simplifies the experimental work flow, increases throughput, and reduces costs while providing excellent data quality. We actively market three instrument systems and eight different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions, diagnostic laboratories, and Ag-Bio companies. We have over 200 customers in 22 countries worldwide.

To achieve and exploit advances in life science research, Ag-Bio and molecular diagnostics, laboratories need robust systems that deliver increased throughput and simpler workflows at decreased costs. Our microfluidic systems are designed to overcome many of the limitations of conventional laboratory systems by integrating an increasing number of fluidic components on a single microfabricated chip. Our technology enables our customers to perform thousands of sophisticated biochemical measurements on samples smaller than the content of a single cell, while utilizing minute volumes of reagents and samples. Similarly, for next generation DNA sequencing, our systems enable rapid preparation of multiple samples in parallel at extremely low costs.

We have successfully commercialized our BioMark and EP1 systems for genetic analysis and our Access Array system for next generation DNA sequencing sample preparation. Researchers and clinicians have successfully employed our products to help achieve breakthroughs in a variety of fields, including genetic variation, cellular function and structural biology. These include using our microfluidic systems to help detect life-threatening mutations in patients’ cancer cells, discover cancer associated biomarkers, analyze the genetic composition of individual stem cells, identify fetal chromosomal abnormalities and assess the quality of agricultural seed products. Also, our Access Array system resolves a critical workflow bottleneck across all commercial next generation DNA sequencing platforms. We believe that the versatility of our microfluidic technology will enable us to develop additional applications across a wide variety of markets.

We have grown our revenues from $6.4 million in 2006 to $25.4 million in 2009 and $23.2 million in the nine months ended September 30, 2010, during which time our product margin has increased from 30 percent in 2006, to 52 percent in 2009 and to 62 percent for the nine months ended September 30, 2010.